Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031

Ligand Pharmaceuticals announced its intention to offer $550 million aggregate principal amount of convertible senior notes due 2031 in a private placement, with initial purchasers receiving a 13-day option to buy an additional $82.5 million. The company expects to use a portion of the net proceeds to enter into convertible note hedge and warrant transactions and to repurchase up to $75 million of its common stock to offset potential dilution upon conversion.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.